Given the poor prognosis associated with the BRAF-V600E mutation in CRC, many oncologists consider first-line triple therapy with FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) with or without bevacizumab for such patients because a subgroup analysis of the TRIBE study demonstrated the benefit of triple (FOLFOXIRI) versus double (FOLFOX (5-FU, Leucovorin, Oxaliplatin) or FOLFIRI (folinic acid, fluorouracil, and irinotecan)) therapy with bevacizumab [17]. The gene discussed is BRAF; the disease is colorectal carcinoma.